A treatment for chronic obstructive pulmonary disease
CN120789080BActive Publication Date: 2026-05-26THE AFFILIATED HOSPITAL OF SOUTHWEST MEDICAL UNIV
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- THE AFFILIATED HOSPITAL OF SOUTHWEST MEDICAL UNIV
- Filing Date
- 2025-09-11
- Publication Date
- 2026-05-26
AI Technical Summary
Technical Problem
Existing technologies for treating chronic obstructive pulmonary disease (COPD) suffer from drug non-responsiveness or significant side effects, and there is a lack of safe and effective treatment methods.
Method used
Syringin is used as the active ingredient, alone or in combination with aminophylline, to relieve airflow obstruction, inhibit airway inflammation and improve pathological damage to lung tissue, and is prepared in a dose of 20-40 mg/kg/day.
Benefits of technology
Syringin significantly relieves airflow obstruction, inhibits airway inflammation, and improves lung tissue damage. Combined use with other medications at low doses enhances efficacy, reduces the dosage and side effects of aminophylline, and provides a safer and more effective treatment approach.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN120789080B_ABST
Abstract
This invention discloses a therapeutic drug for chronic obstructive pulmonary disease (COPD), belonging to the field of medical technology. The active ingredient of this drug is syringin. Experimental results show that syringin can significantly alleviate airflow obstruction, inhibit airway inflammation, and improve lung tissue damage. More importantly, this invention demonstrates the synergistic effect of syringin combined with aminophylline. This combined treatment regimen not only significantly improves efficacy but also significantly reduces the dosage and toxic side effects of aminophylline. Therefore, this invention provides a more efficient and safer innovative drug and its combination therapy strategy for COPD treatment, possessing significant clinical application value.
Need to check novelty before this filing date? Find Prior Art